Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

PROJECT CBD Releases Results of Landmark Survey of Thousands of CBD Consumers

Users Say CBD Helps Most with Pain, Anxiety and Sleep, Has Benefits Across a Wide Range of Diseases and Conditions


HEALDSBURG, CALIFORNIA - September 20, 2019 ( Newswire) PROJECT CBD, a California-based educational non-profit, has released the results of a landmark survey of over 3,500 CBD users from across the United States and around the world.

The organization began collecting responses in early 2019 to chronicle who is using CBD, how and why people are using it, what kinds of products they are consuming, and whether or not CBD is working for them. The analysis covers responses over an eight-month period and is one of the largest data sets available on CBD use to date. PROJECT CBD will continue to collect data, and plans to update results regularly as well as publish in-depth reports on specific conditions.

Among the survey's key findings are:

  • Most users are consuming hemp-derived CBD (as cannabis is not legal in most states or countries) in the form of tinctures or topicals and use it to treat pain (in particular resulting from inflammation), improve mood or sleep, or for general wellness. A small group of respondents (10%) use it to treat severe, debilitating conditions such as epilepsy, MS, autism or Parkinson's Disease.
  • Almost 90% of respondents taking CBD for pain report an improvement in the frequency and duration of their pain, with 60% reporting that CBD made these aspects "much better." Respondents reported their pain intensity decreased by 60% (from an average pain score of 6.85 to 2.76) when taking CBD.
  • CBD dramatically improved sleep, with respondents reporting they were more successful falling asleep (an average of 20 minutes versus over an hour) and staying asleep (waking 1.4 times per night versus 4.3, a two-thirds reduction.) As a result, respondents said they wake up feeling tired less than 10% of the time when using CBD versus nearly 75% of the time.
  • Participants said CBD is very effective in managing anxiety and depression, in particular with reducing feelings of nervousness (68% of respondents using CBD for anxiety said their feelings of nervousness were "much better"). Respondents also cited CBD's ability to relieve panic attacks and mitigate mood swings.
  • Among respondents taking CBD for PTSD, CBD appears to be highly effective in addressing a range of symptoms, particularly anxiety, anger, irritability, depression, mood swings, and panic attacks. CBD also appears helpful, although less so, in diminishing unwanted thoughts, nightmares, and heart palpitations in people with PTSD.

"The survey shows that CBD is astonishingly effective at simply making people feel better," said Tiffany Devitt, author of the results report. "While results make clear it is not a panacea for all that ails us, as some would claim, the survey confirms well-established facts about CBD -- specifically that users find CBD to be safe and effective in managing pain and anxiety resulting from a range of underlying diseases and conditions."

Users were surveyed on CBD's impact on six quality of life measurements: pain, mood, sleep, physical function, energy or motivation, and the ability to socialize. A majority of participants reported some improvement across all measures, but the most significant were in the areas of pain and mood.

This landmark survey also elicited information on seventeen different conditions for which CBD is often used, including ADD or ADHD, Alzheimer's disease, autism spectrum disorder, brain injury (e.g. stroke, TBI, tumor), cancer, diabetes, epilepsy and other seizure disorders, gastrointestinal disease (e.g. Colitis, Crohn's, IBS), depression, anxiety and other mood disorders, motion sickness, pain, Parkinson's disease, hormonal conditions (e.g. PMS, menopause), multiple sclerosis, PTSD, and sleep problems.

The 50-page report, as well as its analysis, is available in its entirety at

Project CBD will make the survey data available to researchers, and hopes the data generated can provide guidance for those seeking therapeutic relief and for those curious about where CBD research might lead.

About Project CBD

Project CBD is a California-based nonprofit dedicated to promoting and publicizing research into the medical uses of cannabidiol (CBD) and other components of the cannabis plant. They provide educational services for physicians, patients, industry professionals, and the general public. Project CBD was established in 2010 by journalists who had been covering the medical marijuana story—the science, the movement and the industry. They felt that the reintroduction of CBD-rich cannabis into the grassroots supply merited special attention. Project CBD emphasizes CBD not to privilege one cannabinoid compound over another but to challenge the idea that cannabis equals THC. THC is a remarkable molecule in its own right, but THC is not the whole plant, and neither is CBD. Project CBD defends and supports whole plant cannabis therapeutics.

Press Contact

Jim Walsh
Project CBD

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks

Buy a cannabis guest post on